A cancer vaccine that has already demonstrated effectiveness when used on malignant melanoma, prostate cancer and lung cancer in studies will be tested on mesothelioma patients. The novel UV1 vaccine, which has also proven to be safe, is being tested by a research team at Oslo University Hospital in Norway as part of a mesothelioma clinical trial along with a promising immunotherapy combination.
UV1 is a peptide-based vaccine designed to induce a specific T-cell response and increase the effectiveness of the immunotherapy drugs. This is the first time UV1 will be studied with mesothelioma cancer, UV1 is a product of Ultimovacs, a pharmaceutical company based in Oslo, Norway. The study will soon move into six other national hospitals, covering Sweden, Spain, Denmark and Australia.
If you or a loved one have been diagnosed with mesothelioma, the attorneys at Nass Cancelliere can help to obtain the compensation you deserve. The Philadelphia-based law firm has assisted thousands of asbestos victims from Pennsylvania, New Jersey and Delaware, and has collected over $100,000,000 in compensation for its clients. The firm has also been instrumental in changing many of the laws in Pennsylvania to help asbestos victims.